-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: Pickup
On April 27, SQZ Biotechnologies announced that the U.
Human papillomavirus (HPV) is one of the most common viruses in the world, and some strains can live in the body for many years, often causing cancer
SQZ-PBMC-HPV is based on the company's technology platform called "Cell Squeeze"
SQZ-PBMC-HPV is developed based on the company's SQZ® APCs platform, which induces a specific T cell response against the antigen by encapsulating the target antigen in APC cells
Data presented at the 2021 ESMO Immuno-Oncology Congress showed that SQZ-PBMC-HPV monotherapy induced radiographic, symptomatic, and immune responses in immune checkpoint PD-1-treated patients with HPV16-positive solid tumors
SQZ-PBMC-HPV is currently being evaluated in a Phase I/II clinical trial for the treatment of patients with HPV16+ advanced or metastatic solid tumors positive for human leukocyte antigen serotype HLA-A*02
Note: The original text has been deleted